Lack of blood pressure salt-sensitivity supports a preglomerular site of action of nitric oxide in type I diabetic rats

Michael W Brands, Tracy D. Bell, Cassandra Fleming, Hicham Labazi, LaShon Sturgis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

1. The relationship between sodium intake and blood pressure is affected differently by changes in angiotensin (Ang) II and preglomerular resistance, and this study measured that relationship to evaluate the link between nitric oxide and blood pressure early in diabetes. 2. Rats were chronically instrumented, placed on high-sodium (HS = 12 mEq/d) or low-sodium (LS = 0.07 mEq/d) intake diets and assigned to either vehicle- (V) or Nω-nitro-L- arginine methyl ester- (L-NAME; L) treated groups. Mean arterial pressure (MAP) was measured 18 h/day for a 6-day control and 14-day streptozotocin diabetic period in each animal. 3. The MAP of the control period averaged 95 ± 1 and 94 ± 1 mmHg in the LSV and HSV rats and 116 ± 2 and 124 ± 1 mmHg in the LSL and HSL rats, respectively (LSL vs HSL was significant at P < 0.05). Diabetes increased MAP only in the LSL and HSL rats to 141 ± 2 mmHg and 152 ± 2, respectively, similar to our previous reports, and those respective 25 and 28 mmHg increases were a parallel shift in the pressure natriuresis relationship. However, the apparent difference between the LSL and HSL groups when compared was a parallel of the control MAP difference. Plasma renin activity (PRA) in the control period averaged 1.5 ± 0.5 and 8.1 ± 1.8 ng AI/mL per h in the HSV and LSV rats, and 0.8 ± 0.2 and 2.8 ± 0.5 ng AI/mL per h in the HSL and LSL rats, respectively, and increased similarly by 4.6-fold in the HSL and 4.8-fold in the LSL rats during diabetes. Glomerular filtration rate (GFR) increased in the vehicle but not the L-NAME-treated groups, consistent with our previous reports. 4. Thus, the hypertension caused by the onset of diabetes in L-NAME-treated rats was not salt-sensitive. The normal modulation of PRA by salt intake and the failure of GFR to increase are consistent with our hypothesis that nitric oxide may protect against hypertension early in diabetes by preventing preglomerular vasoconstriction by AngII.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalClinical and Experimental Pharmacology and Physiology
Volume34
Issue number5-6
DOIs
StatePublished - May 1 2007

Fingerprint

Nitric Oxide
Salts
Blood Pressure
NG-Nitroarginine Methyl Ester
Arterial Pressure
Sodium
Glomerular Filtration Rate
Renin
Hypertension
Natriuresis
Streptozocin
Vasoconstriction
Angiotensin II
Diet
Pressure

Keywords

  • Angiotensin II
  • Diabetes
  • Glomerular filtration rate
  • Hypertension
  • Nitric oxide
  • Salt

ASJC Scopus subject areas

  • Physiology
  • Pharmacology
  • Physiology (medical)

Cite this

Lack of blood pressure salt-sensitivity supports a preglomerular site of action of nitric oxide in type I diabetic rats. / Brands, Michael W; Bell, Tracy D.; Fleming, Cassandra; Labazi, Hicham; Sturgis, LaShon.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 34, No. 5-6, 01.05.2007, p. 475-479.

Research output: Contribution to journalArticle

@article{12010285744f4eea9c24d7475c7d7af5,
title = "Lack of blood pressure salt-sensitivity supports a preglomerular site of action of nitric oxide in type I diabetic rats",
abstract = "1. The relationship between sodium intake and blood pressure is affected differently by changes in angiotensin (Ang) II and preglomerular resistance, and this study measured that relationship to evaluate the link between nitric oxide and blood pressure early in diabetes. 2. Rats were chronically instrumented, placed on high-sodium (HS = 12 mEq/d) or low-sodium (LS = 0.07 mEq/d) intake diets and assigned to either vehicle- (V) or Nω-nitro-L- arginine methyl ester- (L-NAME; L) treated groups. Mean arterial pressure (MAP) was measured 18 h/day for a 6-day control and 14-day streptozotocin diabetic period in each animal. 3. The MAP of the control period averaged 95 ± 1 and 94 ± 1 mmHg in the LSV and HSV rats and 116 ± 2 and 124 ± 1 mmHg in the LSL and HSL rats, respectively (LSL vs HSL was significant at P < 0.05). Diabetes increased MAP only in the LSL and HSL rats to 141 ± 2 mmHg and 152 ± 2, respectively, similar to our previous reports, and those respective 25 and 28 mmHg increases were a parallel shift in the pressure natriuresis relationship. However, the apparent difference between the LSL and HSL groups when compared was a parallel of the control MAP difference. Plasma renin activity (PRA) in the control period averaged 1.5 ± 0.5 and 8.1 ± 1.8 ng AI/mL per h in the HSV and LSV rats, and 0.8 ± 0.2 and 2.8 ± 0.5 ng AI/mL per h in the HSL and LSL rats, respectively, and increased similarly by 4.6-fold in the HSL and 4.8-fold in the LSL rats during diabetes. Glomerular filtration rate (GFR) increased in the vehicle but not the L-NAME-treated groups, consistent with our previous reports. 4. Thus, the hypertension caused by the onset of diabetes in L-NAME-treated rats was not salt-sensitive. The normal modulation of PRA by salt intake and the failure of GFR to increase are consistent with our hypothesis that nitric oxide may protect against hypertension early in diabetes by preventing preglomerular vasoconstriction by AngII.",
keywords = "Angiotensin II, Diabetes, Glomerular filtration rate, Hypertension, Nitric oxide, Salt",
author = "Brands, {Michael W} and Bell, {Tracy D.} and Cassandra Fleming and Hicham Labazi and LaShon Sturgis",
year = "2007",
month = "5",
day = "1",
doi = "10.1111/j.1440-1681.2007.04597.x",
language = "English (US)",
volume = "34",
pages = "475--479",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "5-6",

}

TY - JOUR

T1 - Lack of blood pressure salt-sensitivity supports a preglomerular site of action of nitric oxide in type I diabetic rats

AU - Brands, Michael W

AU - Bell, Tracy D.

AU - Fleming, Cassandra

AU - Labazi, Hicham

AU - Sturgis, LaShon

PY - 2007/5/1

Y1 - 2007/5/1

N2 - 1. The relationship between sodium intake and blood pressure is affected differently by changes in angiotensin (Ang) II and preglomerular resistance, and this study measured that relationship to evaluate the link between nitric oxide and blood pressure early in diabetes. 2. Rats were chronically instrumented, placed on high-sodium (HS = 12 mEq/d) or low-sodium (LS = 0.07 mEq/d) intake diets and assigned to either vehicle- (V) or Nω-nitro-L- arginine methyl ester- (L-NAME; L) treated groups. Mean arterial pressure (MAP) was measured 18 h/day for a 6-day control and 14-day streptozotocin diabetic period in each animal. 3. The MAP of the control period averaged 95 ± 1 and 94 ± 1 mmHg in the LSV and HSV rats and 116 ± 2 and 124 ± 1 mmHg in the LSL and HSL rats, respectively (LSL vs HSL was significant at P < 0.05). Diabetes increased MAP only in the LSL and HSL rats to 141 ± 2 mmHg and 152 ± 2, respectively, similar to our previous reports, and those respective 25 and 28 mmHg increases were a parallel shift in the pressure natriuresis relationship. However, the apparent difference between the LSL and HSL groups when compared was a parallel of the control MAP difference. Plasma renin activity (PRA) in the control period averaged 1.5 ± 0.5 and 8.1 ± 1.8 ng AI/mL per h in the HSV and LSV rats, and 0.8 ± 0.2 and 2.8 ± 0.5 ng AI/mL per h in the HSL and LSL rats, respectively, and increased similarly by 4.6-fold in the HSL and 4.8-fold in the LSL rats during diabetes. Glomerular filtration rate (GFR) increased in the vehicle but not the L-NAME-treated groups, consistent with our previous reports. 4. Thus, the hypertension caused by the onset of diabetes in L-NAME-treated rats was not salt-sensitive. The normal modulation of PRA by salt intake and the failure of GFR to increase are consistent with our hypothesis that nitric oxide may protect against hypertension early in diabetes by preventing preglomerular vasoconstriction by AngII.

AB - 1. The relationship between sodium intake and blood pressure is affected differently by changes in angiotensin (Ang) II and preglomerular resistance, and this study measured that relationship to evaluate the link between nitric oxide and blood pressure early in diabetes. 2. Rats were chronically instrumented, placed on high-sodium (HS = 12 mEq/d) or low-sodium (LS = 0.07 mEq/d) intake diets and assigned to either vehicle- (V) or Nω-nitro-L- arginine methyl ester- (L-NAME; L) treated groups. Mean arterial pressure (MAP) was measured 18 h/day for a 6-day control and 14-day streptozotocin diabetic period in each animal. 3. The MAP of the control period averaged 95 ± 1 and 94 ± 1 mmHg in the LSV and HSV rats and 116 ± 2 and 124 ± 1 mmHg in the LSL and HSL rats, respectively (LSL vs HSL was significant at P < 0.05). Diabetes increased MAP only in the LSL and HSL rats to 141 ± 2 mmHg and 152 ± 2, respectively, similar to our previous reports, and those respective 25 and 28 mmHg increases were a parallel shift in the pressure natriuresis relationship. However, the apparent difference between the LSL and HSL groups when compared was a parallel of the control MAP difference. Plasma renin activity (PRA) in the control period averaged 1.5 ± 0.5 and 8.1 ± 1.8 ng AI/mL per h in the HSV and LSV rats, and 0.8 ± 0.2 and 2.8 ± 0.5 ng AI/mL per h in the HSL and LSL rats, respectively, and increased similarly by 4.6-fold in the HSL and 4.8-fold in the LSL rats during diabetes. Glomerular filtration rate (GFR) increased in the vehicle but not the L-NAME-treated groups, consistent with our previous reports. 4. Thus, the hypertension caused by the onset of diabetes in L-NAME-treated rats was not salt-sensitive. The normal modulation of PRA by salt intake and the failure of GFR to increase are consistent with our hypothesis that nitric oxide may protect against hypertension early in diabetes by preventing preglomerular vasoconstriction by AngII.

KW - Angiotensin II

KW - Diabetes

KW - Glomerular filtration rate

KW - Hypertension

KW - Nitric oxide

KW - Salt

UR - http://www.scopus.com/inward/record.url?scp=33947700480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947700480&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1681.2007.04597.x

DO - 10.1111/j.1440-1681.2007.04597.x

M3 - Article

VL - 34

SP - 475

EP - 479

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 5-6

ER -